Biovest Defines Role of BiovaxID(R) Personalized Cancer Vaccine in Journal of ... MarketWatch (press release) concludes that BiovaxID offers a non-immunosuppressive alternative or potentially complementary approach to rituximab maintenance or radio-immunotherapy as a consolidation therapy for follicular lymphoma in first remission. By its mechanism of action, ... |
